Skip to content

Clinical study on prevention and treatment of postherpetic neuralgia with whole-course anti-virus based on viral fluorescence quantitative PCR

Clinical study on prevention and treatment of postherpetic neuralgia with whole-course anti-virus based on viral fluorescence quantitative PCR

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000037264
Enrollment
Unknown
Registered
2020-08-27
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

control group:Intervention with valacyclovir for 1 week
experimental group:Intervention with valacyclovir for 2 weeks

Sponsors

Shanghai Dermatology Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Meet the diagnostic criteria for herpes zoster and meet the age criteria for middle-aged and elderly people:? (1) Aged >= 50 to 79 years; (2) The course of disease is less than one week; ?? (3) Patients without antiviral and analgesic treatment; ?? (4) Those who voluntarily sign an informed consent form and are willing to actively cooperate with treatment.

Exclusion criteria

Exclusion criteria: (1) People with special types of herpes zoster; ?? (2) Combined with life-threatening primary diseases such as cardiovascular, cerebrovascular, liver, lung, kidney, hematopoietic system, and other endocrine system diseases or systemic diseases that manifest as fibromyalgia, such as osteoporosis, severe trauma, and malignancy Tumors, etc.; (3) Female patients during pregnancy or lactation; (4) People with allergies or physical weakness and intolerance.

Design outcomes

Primary

MeasureTime frame
Comprehensive efficacy evaluation;Blistering time;Scab time;Sensory nerve quantification;Visual analog scale;Viral nucleic acid quantitative PCR detection;Dermatology Life Quality Index, DLQI;Safety evaluation;

Countries

China

Contacts

Public ContactWencheng Jiang

Shanghai Dermatology Hospital

drjiangwencheng@163.com+86 13816401860

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026